Showing results (221-230 of 419) with videos related to
Sort By:
Pageof 42
Cancer Medicine|February 24, 2024
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumorsNiamh Coleman, Bettzy Stephen, Siqing Fu, et al.Oral Oncology|June 23, 2024
Patient perceptions underlying ctDNA molecular surveillance for HPV(+) oropharyngeal squamous cell carcinomaAmanda J Bastien, Jewel Ng, Iris Cong, et al.Surgery|October 26, 2019
Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinomaJessica E Maxwell, Maria K Gule-Monroe, Vivek Subbiah, et al.Head & Neck|November 10, 2020
Neoadjuvant selpercatinib for advanced medullary thyroid cancerYelda Jozaghi, Mark Zafereo, Michelle D Williams, et al.Journal of Immunotherapy and Precision Oncology|June 6, 2022
Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic CholangiocarcinomaTimothy P DiPeri, Mehmet Demirhan, Daniel D Karp, et al.Investigational New Drugs|January 8, 2021
The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trialJeffrey A How, Amir Jazaeri, Shannon N Westin, et al.Journal of Cutaneous Pathology|July 19, 2018
Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumorKrishna Arudra, Ravi Patel, Michael T Tetzlaff, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2017
Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid TumorsVivek Subbiah, Juneko E Grilley-Olson, Austin J Combest, et al.JCO Precision Oncology|April 23, 2025
Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion CancerMarcia S Brose, C Benedikt Westphalen, Xiaoyun Pan, et al.Experimental Hematology & Oncology|April 28, 2020
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trialVivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, et al.Pageof 42